These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4917 related articles for article (PubMed ID: 6302253)

  • 1. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin.
    Chakravarty PK; Carl PL; Weber MJ; Katzenellenbogen JA
    J Med Chem; 1983 May; 26(5):638-44. PubMed ID: 6302253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
    Chakravarty PK; Carl PL; Weber MJ; Katzenellenbogen JA
    J Med Chem; 1983 May; 26(5):633-8. PubMed ID: 6221099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protease-activated "prodrugs" for cancer chemotherapy.
    Carl PL; Chakravarty PK; Katzenellenbogen JA; Weber MJ
    Proc Natl Acad Sci U S A; 1980 Apr; 77(4):2224-8. PubMed ID: 6246527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug.
    de Groot FM; Broxterman HJ; Adams HP; van Vliet A; Tesser GI; Elderkamp YW; Schraa AJ; Kok RJ; Molema G; Pinedo HM; Scheeren HW
    Mol Cancer Ther; 2002 Sep; 1(11):901-11. PubMed ID: 12481411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
    Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
    Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin.
    de Groot FM; de Bart AC; Verheijen JH; Scheeren HW
    J Med Chem; 1999 Dec; 42(25):5277-83. PubMed ID: 10602713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
    Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
    Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
    Khan SR; Denmeade SR
    Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New fluorogenic peptide substrates for plasmin.
    Kato H; Adachi N; Ohno Y; Iwanaga S; Takada K; Sakakibara S
    J Biochem; 1980 Jul; 88(1):183-90. PubMed ID: 6447693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
    Devalapally H; Rajan KS; Akkinepally RR; Devarakonda RK
    Drug Dev Ind Pharm; 2008 Aug; 34(8):789-95. PubMed ID: 18608462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
    Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
    Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
    van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
    Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes.
    Berkenpas MB; Quigley JP
    Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7768-72. PubMed ID: 1652763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
    Warnecke A; Fichtner I; Sass G; Kratz F
    Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
    de Groot FM; van Berkom LW; Scheeren HW
    J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Si113-prodrugs selectively activated by plasmin against hepatocellular and ovarian carcinoma.
    Rango E; D'Antona L; Iovenitti G; Brai A; Mancini A; Zamperini C; Trivisani CI; Marianelli S; Fallacara AL; Molinari A; Cianciusi A; Schenone S; Perrotti N; Dreassi E; Botta M
    Eur J Med Chem; 2021 Nov; 223():113653. PubMed ID: 34161866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 246.